An observational study in Abdominal Aortic Aneurysm and Cardiovascular Events, sponsored by Rijnstate Hospital. Recruiting at 7 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-06.
Sponsored by Rijnstate Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Aortic Aneurysm, Abdominal by Rijnstate Hospital — 2 open to participants now, 3 under way, none of them phase 3. Aortic Aneurysm, Abdominal · Rijnstate Hospital.
Among the 13 studies in Aortic Aneurysm, Abdominal by Rijnstate Hospital, this one is the 4th largest by planned enrollment of the 10 observational ones that give a count, is the only one that started in 2020, is one of 10 observational ones, and was the 7th registered.
467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.
Browse Aortic Aneurysm, Abdominal studies →2 of the 13 studies in Aortic Aneurysm, Abdominal by Rijnstate Hospital are open now, in 8 countries. Recruiting first, the newest first:
Rijnstate Hospital · Sites in United States, France, Germany and 5 more countries
Ages 18+
By country, each count listing its studies:
Of the 66 Aortic Aneurysm, Abdominal studies recruiting now, 52 (79%) set no upper age limit and 3 (5%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2020.
This study's planned enrollment of 194 is above the median of 165 across 217 observational studies indexed under Aortic Aneurysm, Abdominal.
Median enrollment 20 across the 3 interventional studies, 134 across the 10 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Rijnstate Hospital is the lead sponsor of 130 studies on the registry; 13 are open to participants now.
1 of the studies in Aortic Aneurysm, Abdominal by Rijnstate Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04183426Rijnstate HospitalTonometry(1) and Duplex Ultrasound(2) to Predict CV Events in to be Treated Patients With an AAA | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Aortic Aneurysm, Abdominal by Rijnstate Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Abdominal aortic aneurysm (AAA) is a common vascular disease and associated with risk of rupture, but also with a high cardiovascular (CV) event rate. A key difficulty in AAA is predicting these life-threatening complications, which are strongly linked to vascular health. In 2013, the SMART risk score was developed to calculate the risk of the patients for recurrent vascular events based on clinical characteristics. Recently, a novel, easy to perform, non-invasive test of endothelial function (the carotid artery reactivity (CAR) test), reflecting target organ damage, has been introduced. The CAR is a simple, quick (5-min), non-invasive test that uses ultrasound to examine the carotid artery in response to sympathetic stimulation by placing one hand in cold water. This test shows strong agreement with both coronary and aortic responses to sympathetic stimulation and predicted CV-events in patients with peripheral arterial disease.
The aim of this prospective 2-year follow-up study is to investigate the predictive capacity of the CAR-test for development of CV-events after elective AAA repair in comparison to the SMART risk score. Secondary objectives are to investigate the predictive capacity of arterial stiffness measurements and the post-operative CAR-test for development of CV-events and to evaluate health status scores to provide insight if these scores can support clinical decision making.
The investigators will include 194 patients with an AAA who will be scheduled for repair. Participants will be recruited from all collaborating hospitals (currently Radboudumc, Rijnstate, CWZ) after providing written informed consent.
In this observational, prospective study, a total of 194 patients who are going to be treated for their AAA will be included. Baseline patient characteristics will be registered, including traditional risk factors and CV-history. In addition to regular care of measuring AAA diameter progression (in mm/year), we will perform the CAR-test (10-min) and non-invasive arterial stiffness measures (PWA and PWV) with the SphygmoCor device (10-min).
Furthermore, the investigators will ask patients to complete a questionnaire about the quality of their life. A second questionnaire tries to clarify the disease experience of the patients. Both questionnaires will be asked to be completed at the start, 6-8 weeks after repair, after one year and after two years of repair. Subsequently, the investigators will record major adverse cardiovascular events (MACE) according to the International Classification of Disease-10. Registration of MACE will be performed using hospital-records and following international guidelines. Across a 2-year follow-up, by means of regular follow-up appointments, the investigators will examine the ability of the CAR parameter and arterial stiffness parameters to predict CV-events.
Patients with an AAA who will be scheduled for repair, will be included. AAA patients will be recruited from all collaborating hospitals (Radboudumc, Rijnstate, CWZ), who provide written informed consent. Additionally, also AAA-patients under surveillance of general practitioners are eligible (and will be contacted through the hospital-links), since the nature of the tests allow for performing all tests at the general practitioners' office.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The CAR test will be applied to stimulate the sympathetic nervous system. This thermal stimulus is known to elevate blood pressure via sympathetic pathways, so it can be used to study the vascular response to sympathetic activation. The participant will submerge their left hand in a bucket of ice water (approximately 4 degrees celcius) for 3 minutes, which is reported to be sufficient to induce a maximal dilation in the common carotid artery. At baseline and every minute after the hand is submerged in ice water, the blood pressure will be measured to check whether a sympathetic stimulation is achieved.
The SphygmoCor device will be used to non-invasively measure arterial stiffness parameters using applanation tonometry. For Pulse Wave Analyses (PWA), the radial waveform will be recorded. Approximately 10 waveforms are averaged, resulting in several non-invasive parameters: * Peripheral pressure parameters * Central and abdominal aneurysm pressure parameters (derived using a transfer function) * Cardiac output parameters (sub-endocardial viability ratio (SEVR), Ejection Duration (ED)) Pulse wave velocity will be performed by recording the waveforms of the carotid and femoral artery sequentially. The travelled distance will be measured according to the current guidelines and entered in the program. The program will calculate the PWV based on 10 ECG triggered waveform of each artery.
Major Adverse Cardiovascular Events (MACE)
Incidence of MACE, including myocardial infarction, cerebral infarction, heart failure, rupture, and peripheral vascular disease
Time frame: 2-year follow-up
SMART Risk score
Second Manifestations of ARTerial disease risk score is developed to determine the risk of recurrent vascular events based on clinical characteristics of the patients
Time frame: Baseline
CAR-test results
Percentage of vasodilation/vasoconstriction to the CAR test at the common carotid artery at baseline
Time frame: Baseline and 6-weeks after operation
CAR-test results
Magnitude of the blood flow and perfusion response
Time frame: Baseline and 6-weeks after operation
CAR-test results
Timing of the blood flow and perfusion response
Time frame: Baseline and 6-weeks after operation
CAR-test results
Blood pressure responses
Time frame: Baseline and 6-weeks after operation
CAR-test results
Heart rate responses
Time frame: Baseline and 6-weeks after operation
CAR-test results
Changes after treatment
Time frame: Baseline and 6-weeks after operation
SphygmoCor parameters
Peripheral pressure measurements (PWA)
Time frame: Baseline, 6-weeks, 1 year and 2 year after operation
SphygmoCor parameters
Central pressure measurements (derived using a transfer function, PWA)
Time frame: Baseline, 6-weeks, 1 year and 2 year after operation
SphygmoCor parameters
Abdominal pressure measurements (derived using a transfer function, PWA)
Time frame: Baseline, 6-weeks, 1 year and 2 year after operation
SphygmoCor parameters
SEVR
Time frame: Baseline, 6-weeks, 1 year and 2 year after operation
SphygmoCor parameters
ED
Time frame: Baseline, 6-weeks, 1 year and 2 year after operation
SphygmoCor parameters
PWV
Time frame: Baseline, 6-weeks, 1 year and 2 year after operation
SphygmoCor parameters
Change in Peripheral pressure measurements (PWA) after treatment
Time frame: Baseline and 6-weeks after operation
SphygmoCor parameters
Change in Central pressure measurements (derived using a transfer function, PWA) after treatment
Time frame: Baseline and 6-weeks after operation
SphygmoCor parameters
Change in Abdominal pressure measurements (derived using a transfer function, PWA) after treatment
Time frame: Baseline and 6-weeks after operation
SphygmoCor parameters
Change in SEVR after treatment
Time frame: Baseline and 6-weeks after operation
SphygmoCor parameters
Change in ED after treatment
Time frame: Baseline and 6-weeks after operation
SphygmoCor parameters
Change in PWV after treatment
Time frame: Baseline and 6-weeks after operation
Score EQ-5D questionnaire
Patient reported outcomes measured by the general health questionnaire
Time frame: Baseline, 6-weeks, 1 year and 2 year after operation
Score IPQ-K questionnaire
Patient reported outcomes measured by the disease perception questionnaire
Time frame: Baseline, 6-weeks, 1 year and 2 year after operation
Demographic characteristics
Age
Time frame: Baseline
Demographic characteristics
Gender
Time frame: Baseline
Demographic characteristics
If current smoker
Time frame: Baseline
Demographic characteristics
Height
Time frame: Baseline
Demographic characteristics
Weight
Time frame: Baseline
Demographic characteristics
ASA class
Time frame: Baseline
Demographic characteristics
Medical history
Time frame: Baseline
Demographic characteristics
Blood pressure
Time frame: Baseline
Demographic characteristics
Heart rate
Time frame: Baseline
Demographic characteristics
Cardiac measurements
Time frame: Baseline
Demographic characteristics
SVS class
Time frame: Baseline
Preoperative anatomic characteristics before primary repair procedure
AAA sac diameter
Time frame: Baseline
Preoperative anatomic characteristics before primary repair procedure
Infrarenal aortic neck lumen diameter
Time frame: Baseline
Preoperative anatomic characteristics before primary repair procedure
Proximal non-aneurysmal aortic neck length
Time frame: Baseline
Preoperative anatomic characteristics before primary repair procedure
Proximal aortic neck angle
Time frame: Baseline
Preoperative anatomic characteristics before primary repair procedure
Aneurysm blood lumen diameter
Time frame: Baseline
Preoperative anatomic characteristics before primary repair procedure
Common iliac artery diameters
Time frame: Baseline
Preoperative anatomic characteristics before primary repair procedure
Blood lumen diameter
Time frame: Baseline
Procedure and discharge details of intervention
Type of procedure
Time frame: At time of procedure
Procedure and discharge details of intervention
Anesthesia type
Time frame: At time of procedure
Procedure and discharge details of intervention
Access type
Time frame: At time of procedure
Procedure and discharge details of intervention
Used stent lengths
Time frame: At time of procedure
Procedure and discharge details of intervention
Contrast volume used
Time frame: At time of procedure
Procedure and discharge details of intervention
Total procedure time
Time frame: At time of procedure
Procedure and discharge details of intervention
Immediate procedural technical success
Time frame: At time of procedure
Procedure and discharge details of intervention
Complications pre procedure
Time frame: During procedure
Procedure and discharge details of intervention
Complications post procedure
Time frame: Up to 2 years
Procedure and discharge details of intervention
Additional procedures estimated blood loss
Time frame: During procedure
Procedure and discharge details of intervention
Blood transfusion
Time frame: During procedure
Procedure and discharge details of intervention
Concomitant procedures
Time frame: Up to 2 years
Procedure and discharge details of intervention
Time in ICU
Time frame: After procedure till discharge
Procedure and discharge details of intervention
Time to hospital discharge
Time frame: After procedure till discharge
Medications
Dose of Anti-platelets
Time frame: During 2-year follow up
Medications
Dose of Anti-coagulants
Time frame: During 2-year follow up
Medications
Dose of Anti-hypertensives
Time frame: During 2-year follow up
Medications
Dose of Statins
Time frame: During 2-year follow up
Medications
Dose of Beta-blockers
Time frame: During 2-year follow up
Medications
Dose of Sympathicomimetics
Time frame: During 2-year follow up
Laboratory test results
Hemoglobin
Time frame: 2-year follow-up
Laboratory test results
Serum creatinine
Time frame: 2-year follow-up
Laboratory test results
Cholesterol
Time frame: 2-year follow-up
Laboratory test results
eGFR
Time frame: 2-year follow-up
Laboratory test results
CRP
Time frame: 2-year follow-up
Parameters during follow-up
Any type of endoleak
Time frame: 2-year follow-up
Parameters during follow-up
AAA sac expansion
Time frame: 2-year follow-up
Parameters during follow-up
Any other (S)AE
Time frame: 2-year follow-up
Started Jun 2020 (actual). Primary completion is estimated for Dec 2026, 78 months after the start.
Of 67 non-industry observational studies under Aortic Aneurysm, Abdominal, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 83. This study's planned 78 months is above that.
Counting every sponsor, half of 91 studies reached it within 48 months; a quarter within 24 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.